Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

PellePharm

PellePharm
2012 FOUNDED
PRIVATE STATUS
Corporate LATEST DEAL TYPE
$70M LATEST DEAL AMOUNT
7 INVESTORS
Description

Developer of skin cancer therapeutics intended to mitigate the tumor burden with basal cell carcinomas. The company's therapeutics include topical hedgehog inhibitor which decreases the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • 101 Mission Street
  • Suite 2050
  • San Francisco, CA
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore PellePharm’s full profile, request a free trial.

PellePharm Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Corporate 20-Nov-2018 $70M 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 18-Jun-2018 00.00 000.00 Completed Clinical Trials - Phase 2
4. Debt - General 29-Mar-2018 00.00 000.00 Completed
3. Early Stage VC (Series B2) 31-Jul-2017 0000 000.00 0000 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 23-Jul-2015 $4.55M $7.67M 000.00 Completed Startup
1. Early Stage VC (Series A) 11-May-2015 $3.12M $3.12M 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

PellePharm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B2 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 3,712,649 $0.000100 $0.84 $0.84 1x $0.84 12.07%
To view this company’s complete Cap Table, request access »

PellePharm Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
LEO Pharma Corporation Minority 000 0000 000000 0
Aisling Capital Venture Capital Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
BridgeBio Corporation Minority 000 0000 000000 0
The Atlanta Trust Other Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

PellePharm Executive Team (5)

Name Title Board
Seat
Contact
Info
Sanuj Ravindran MD Chief Executive Officer, President & Board Member
Ervin Epstein MD Co-Founder, President, Chief Medical Officer & Board Member
Philip Beachy Ph.D Co-Founder
Gerd Kochendoerfer Ph.D Senior Vice President & Head of Operations

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

PellePharm Board Members (5)

Name Representing Role Since Contact
Info
Ervin Epstein MD PellePharm Co-Founder, President, Chief Medical Officer & Board Member 000 0000
Frank McCormick Ph.D Self Board Member 000 0000
Jean Tang MD PellePharm Board Member & Co-Founder 000 0000
Katrin Andreasson PellePharm Board Member 000 0000
Neil Kumar Ph.D BridgeBio Board Member 000 0000